PL2108366T3 - Idebenon stosowany w leczeniu chorób układu oddechowego towarzyszących dystrofii mięśniowej - Google Patents

Idebenon stosowany w leczeniu chorób układu oddechowego towarzyszących dystrofii mięśniowej

Info

Publication number
PL2108366T3
PL2108366T3 PL08007069T PL08007069T PL2108366T3 PL 2108366 T3 PL2108366 T3 PL 2108366T3 PL 08007069 T PL08007069 T PL 08007069T PL 08007069 T PL08007069 T PL 08007069T PL 2108366 T3 PL2108366 T3 PL 2108366T3
Authority
PL
Poland
Prior art keywords
idebenone
muscular dystrophy
treatment
respiratory illness
illness
Prior art date
Application number
PL08007069T
Other languages
English (en)
Inventor
Gunnar Buyse
Thomas Meier
Original Assignee
Santhera Pharmaceuticals Schweiz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39691216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2108366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santhera Pharmaceuticals Schweiz Ag filed Critical Santhera Pharmaceuticals Schweiz Ag
Publication of PL2108366T3 publication Critical patent/PL2108366T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL08007069T 2008-04-09 2008-04-09 Idebenon stosowany w leczeniu chorób układu oddechowego towarzyszących dystrofii mięśniowej PL2108366T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08007069A EP2108366B1 (en) 2008-04-09 2008-04-09 Idebenone for the treatment of respiratory illness in muscular dystrophy

Publications (1)

Publication Number Publication Date
PL2108366T3 true PL2108366T3 (pl) 2012-03-30

Family

ID=39691216

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08007069T PL2108366T3 (pl) 2008-04-09 2008-04-09 Idebenon stosowany w leczeniu chorób układu oddechowego towarzyszących dystrofii mięśniowej

Country Status (17)

Country Link
US (1) US20110092469A1 (pl)
EP (1) EP2108366B1 (pl)
JP (1) JP2011516513A (pl)
AT (1) ATE529104T1 (pl)
AU (1) AU2009235681B2 (pl)
CA (1) CA2719440C (pl)
CY (1) CY1112313T1 (pl)
DK (1) DK2108366T3 (pl)
ES (1) ES2370607T3 (pl)
HR (1) HRP20110813T1 (pl)
MX (1) MX2010011099A (pl)
NZ (1) NZ588181A (pl)
PL (1) PL2108366T3 (pl)
PT (1) PT2108366E (pl)
SI (1) SI2108366T1 (pl)
WO (1) WO2009124693A1 (pl)
ZA (1) ZA201006905B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
EP2620141A1 (en) * 2012-01-25 2013-07-31 Santhera Pharmaceuticals (Schweiz) AG Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative
WO2014035356A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Tablet formulations comprising a quinone derivative active agent
CN103040779B (zh) * 2013-01-01 2015-04-15 刘炜 用于神经系统疾病的口服固体药物组合物
NZ732507A (en) * 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
CN109364050B (zh) * 2018-10-19 2021-02-02 大连医科大学 艾地苯醌在制备治疗肺动脉高压药物中的应用
US20220175800A1 (en) * 2019-04-12 2022-06-09 Ptc Therapeutics Inc. Dispersible tablet composition
US20240269091A1 (en) 2021-06-07 2024-08-15 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51128932A (en) 1975-04-30 1976-11-10 Takeda Chem Ind Ltd Organic compounds
JPH11116470A (ja) 1997-08-12 1999-04-27 Takeda Chem Ind Ltd イデベノン含有経皮投与製剤
AU8562998A (en) 1997-08-12 1999-03-01 Takeda Chemical Industries Ltd. Idebenone-containing preparation for percutaneous administration
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
EP1861080B1 (en) * 2005-03-21 2010-05-26 Santhera Pharmaceuticals (Schweiz) AG Idebenone for the treatment of muscular dystrophies
EP1891946A1 (en) 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone

Also Published As

Publication number Publication date
PT2108366E (pt) 2011-11-10
HRP20110813T1 (hr) 2011-11-30
NZ588181A (en) 2011-11-25
ATE529104T1 (de) 2011-11-15
ES2370607T3 (es) 2011-12-20
CA2719440A1 (en) 2009-10-15
EP2108366A1 (en) 2009-10-14
EP2108366B1 (en) 2011-10-19
AU2009235681A1 (en) 2009-10-15
CA2719440C (en) 2013-07-16
MX2010011099A (es) 2010-11-01
CY1112313T1 (el) 2015-12-09
JP2011516513A (ja) 2011-05-26
SI2108366T1 (sl) 2012-01-31
WO2009124693A1 (en) 2009-10-15
ZA201006905B (en) 2011-06-29
AU2009235681B2 (en) 2012-04-05
DK2108366T3 (da) 2012-01-30
US20110092469A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
ZA201006905B (en) Quinone derivative 2,3-dimerhoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
IN2012DN00908A (pl)
IL198922A0 (en) Chemical compounds and uses
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
MY173616A (en) Compositions and methods for lowering triglycerides
WO2009129246A3 (en) Compositions and methods for preparing and using same
GB0710529D0 (en) Vaccine
IT1394528B1 (it) Apparecchiatura modulare per il trattamento dell'aria, particolarmente per ambienti classificati e per processi produttivi di alimenti in genere.
MX2009012835A (es) Metodo de administracion de un tensioactivo pulmonar.
ZA201109086B (en) Prevention and treatment of allergic diarrhoea
MX2014014369A (es) Metodo para manufacturacion de un documento de valor.
PL2213269T3 (pl) Osobisty środek transportu, na przykład wózek inwalidzki, oraz przeznaczony do niego zespół ramy
UA102414C2 (ru) Циклоундекадепсипептидные соединения для лечения инфекций, вызванных вирусом гепатита с
EP2170932A4 (en) COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
NZ606276A (en) Fastening Means
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
WO2009158511A8 (en) Factor viii muteins with reduced immunogenicity
MX2007011571A (es) Derivado de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4- benzoquinona para el tratamiento de distrofias musculares.
WO2010115078A3 (en) Method of treating cognitive impairment
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
Busch Introduction to the Special Section.
WO2009138987A3 (en) Molecules interfering with binding of calbindin to inositol monophosphatase for the treatment of mood disorders
PL2066314T3 (pl) Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji